drospirenone/ethinyl estradiol / Generic mfg. - LARVOL DELTA

Ovulation induction with oral contraception alone in biochemical to overt primary ovarian insufficiency: a pilot study. (ChiCTR) - P=N/A | N=32 | Not yet recruiting | Sponsor: Xiangya Hospital, Central South University; Xiangya Hospital, Central South University

New trial • Endocrine Disorders • Women's Health

Drug-associated deep vein thrombosis: a disproportionality analysis of the FDA adverse event reporting system (FAERS) database. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "The ten highest-ranking agents by case count were drospirenone/ethinyl estradiol (ROR 69.09), ethinyl estradiol/etonogestrel (ROR 43.41), lenalidomide (ROR 4.89), testosterone (ROR 30.13), rofecoxib (ROR 5.41), ethinyl estradiol/norelgestromin (ROR 28.53), bevacizumab (ROR 3.53), thalidomide (ROR 9.26), pomalidomide (ROR 3.18), and celecoxib (ROR 3.90). This large-scale pharmacovigilance analysis identifies robust DVT signals across multiple drug classes, notably hormonal therapies, immunomodulators, and targeted anticancer agents. The results highlight the importance of proactive thrombotic risk assessment and monitoring in clinical practice when using these medications."

Adverse events • Journal • Cardiovascular • Hematological Disorders • Oncology • Thrombosis • Venous Thromboembolism

A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals

New P1 trial • Oncology

PCOS FAI CHC: Effect of Drospirenone-Ethinyl Estradiol (20microgram vs 30 Microgram) on Free Androgen Index in PCOS (clinicaltrials.gov) - P=N/A | N=60 | Completed | Sponsor: Mst.Sumyara Khatun

New trial • Polycystic Ovary Syndrome

Differences in Verbal Memory, Visuospatial Ability, and Cognitive Inhibition Among Young Women Using Drospirenone and Ethinyl Estradiol Oral Contraceptives Versus Naturally Cycling Controls. (PubMed, Acta Neuropsychiatr) - "The present findings suggest that the use of DRSP/EE oral contraceptives is associated with differences across specific cognitive domains compared to naturally cycling women in the LP. The observed pattern -lower performance in hippocampus-related domains (verbal memory and visuospatial ability) paired with higher performance on a frontal-lobe-dependent task (cognitive inhibition)- is consistent with existing evidence suggesting that suppression of endogenous ovarian hormones may differentially influence cognitive functions. These behavioral associations underscore the need for further domain-specific research into the long-term cognitive implications of combined oral contraceptives."

Journal

A fast method based on programmed temperature vaporization-mass spectrometry for the quantification of 17α-ethinylestradiol and drospirenone in contraceptive formulations. (PubMed, Anal Methods) - "Intra- and inter-day precision were adequate, with values of relative standard deviation (% RSD) equal to or less than 9% and 11%, respectively. Furthermore, the sustainability profile of the proposed rapid method was evaluated using the HEXAGON algorithm, which demonstrated that the PTV-MS method contributes to sustainable development by benefiting both the environment and society."

Journal

Case Report: Menstrual cycle-related psychosis in bipolar I disorder, remitting with a combined oral contraceptive. (PubMed, Front Psychiatry) - "We report a case with two uncommon features: paradoxical relapse during antipsychotic-induced amenorrhea with hyperprolactinemia, and sustained remission after adjunctive hormonal stabilization using a combined oral contraceptive (drospirenone-ethinyl estradiol)...For patients who show clear cycle-linked exacerbations despite antipsychotics and mood stabilizers, endocrine stabilization with a combined oral contraceptive may be considered. Operationally, we coded the case as Bipolar I disorder (DSM-5-TR/ICD-11) based on a syndromal manic episode, while phenotypically it showed a menstrual cycle-related (catamenial) pattern-regular cycle-linked, perimenstrual exacerbations with complete inter-episode remission-distinguishing it from non-catamenial bipolar and other psychotic disorders."

Journal • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry • Women's Health

Delayed start of estetrol drospirenone versus ethinyl estradiol gestodene for ovulation inhibition in a noninferiority randomized controlled trial. (PubMed, Sci Rep) - P=N/A | "Cervical mucus profiles and adverse events, including unscheduled bleeding, did not differ significantly between the groups. Initiating E4/DRSP on cycle day 7-9 appears comparable to that of EE/GS for ovulation inhibition; however, high ovulation rates limit the confirmation of non-inferiority.Clinical trial registration: ClinicalTrials.gov Registration on April 25, 2024 (ID: NCT06396221; https://clinicaltrials.gov/study/NCT06396221 )."

Head-to-Head • Journal

Drug exposure before and during pregnancy and thromboembolic events: a disproportionality analysis from the FAERS database. (PubMed, Int J Surg) - "Drawing on the FAERS database, we have provided a list of drugs with risk signals for PTEs in this exploratory study. Our findings highlight the importance of considering both before and during-pregnancy drug exposures when assessing thromboembolism risk. More well-designed studies are warranted for drugs whose association with PTEs is not fully understood."

Journal • Cardiovascular

Cyproterone acetate for hirsutism. (PubMed, Cochrane Database Syst Rev) - "There were some differences in clinical outcome between CPA and spironolactone, CPA and flutamide, and CPA and finasteride. There were no clinical differences between CPA and the other medical therapies, possibly because of small study size, lack of standardised assessment and objective determinants of improvement in many studies. There are insufficient data presented to compare the adverse effects of all the treatment options. Larger, carefully designed studies are needed to compare efficacy and safety profiles between the therapeutic options available."

Clinical • Journal • Review • Gynecology

Hair cortisol/cortisone in combined oral contraceptive users: An exploratory analysis. (PubMed, Contraception) - "COC use was not associated with higher hair glucocorticoids, though hair treatments may influence detection."

Journal

Effects of drospirenone and ethinylestradiol tablets (II) combined with metformin on the composition of gut microbiota in polycystic ovary syndrome with insulin resistance. (PubMed, Front Endocrinol (Lausanne)) - "2. Drospirenone and ethinylestradiol tablets (II) combined with metformin tablets can change the gut microbiota relative abundance of patients with PCOS-IR, which may be related to the improvement of host lipid and glucose metabolism."

Journal • Polycystic Ovary Syndrome

Comparative Effectiveness of COCPs Versus Levonorgestrel and Other Therapies in Female Acne: A Systematic Review and Meta-Analysis (EADV 2025) - "Materials & A systematic search was performed to identify randomized controlled trials (randomized controlled trials) comparing combined oral contraceptives (e.g., ethinyl estradiol with drospirenone, norgestimate, desogestrel, or chlormadinone acetate) against levonorgestrel-only pills, topical agents, or combination therapies for the treatment of acne. Combined oral contraceptives are effective and safe options for the treatment of acne in women, with enhanced benefits observed when used in conjunction with other treatment modalities. Despite high heterogeneity in reported outcomes and treatment protocols, the evidence supports the use of combined oral contraceptives, particularly formulations containing ethinyl estradiol with drospirenone or ethinyl estradiol with norgestimate. Future clinical trials should aim for standardized reporting of acne severity and direct head-to-head comparisons between contraceptive formulations to better inform optimal treatment..."

HEOR • Retrospective data • Review • Acne Vulgaris • Seborrheic Dermatitis

A Drug-Drug Interaction Study Between HS-10374 Tablets and Drospirenone and Ethinyl Estradiol Tablets(Yasmin®) (clinicaltrials.gov) - P1 | N=18 | Completed | Sponsor: Hansoh BioMedical R&D Company

New P1 trial • Dermatology • Immunology • Psoriasis

Uterine arteries embolization for cesarean scar pregnancy with uterine arteriovenous fistula. (PubMed, SAGE Open Med Case Rep) - "After the operation, leprorelin 3.75 mg was given by intramuscular injection three times, followed by oral contraceptive drospirenone ethinylestradiol tablets, one tablet a day, to prevent recurrence of uterine arteriovenous fistula...Uterine arteriovenous fistula should be considered in the clinical treatment of patients with abnormal vaginal bleeding who cannot be diagnosed clearly. Uterine arteriography is the definitive method, and after interventional treatment, drugs can be used to prevent recurrence and close follow-up."

Journal • Cardiovascular • Hematological Disorders • Postpartum Hemorrhage

Effects of estetrol/drospirenone versus ethinyl estradiol/drospirenone on glucose tolerance in women with polycystic ovary syndrome: A randomised controlled trial. (PubMed, Diabetes Obes Metab) - "E4/DRSP was not inferior to EE/DRSP in its effects on glucose tolerance, insulin levels and HOMA-IR, supporting its use as a potential oral contraceptive option in women with PCOS."

Journal • Polycystic Ovary Syndrome

Oral contraceptives containing ethinyl estradiol and drospirenone increase hydroxylation and methylation of endogenous estrogen but not genotoxic estrogen DNA-adduct formation. (PubMed, Sci Rep) - "Our data suggests that the use of EE/DRSP increases the flux of endogenous hormones into the hormone biotransformation pathway, resulting in increased conversion of estrogens (especially E1) into conjugated, catechol, and methylated estrogens but that the latter is limited by methyl-group donor availability. Interestingly, the increased oxidation of estrogens in COC users does not result in increased DNA-adduct formation."

Journal • Breast Cancer • Oncology • Solid Tumor • COMT

Two Cases of Reduced Mother's Milk Production During Use of Combined Oral Contraceptives. (PubMed, J Hum Lact) - "These cases follow two experiences of low milk production after initiation of combined oral contraceptives. In these cases, there was a resolution of infant weight gain with discontinuation of the medication."

Journal

A Case of the Irregularly Bordered Thyroid nodule (ENDO 2025) - "She had no signs of thyroid dysfunction and was taking fluticasone, cetirizine, and drospirenone/ethinyl estradiol. This case highlights the challenges of managing thyroid nodules with indeterminate cytology and intermediate-risk molecular findings. Despite the benign final diagnosis, the decision to proceed with surgery was influenced by concerning ultrasound features and the molecular profile. With the increasing number of FNA biopsies performed, this case raises the question of whether a more conservative approach with serial imaging could have been an alternative."

Clinical • Allergic Rhinitis • Endocrine Disorders • Immunology • Oncology • Otorhinolaryngology • Polycystic Ovary Syndrome • NRAS

Isotretinoin-Induced Hypertriglyceridemia: A Silent Trigger for Acute Pancreatitis in a Young Patient" (ENDO 2025) - "Her only medications were drospirenone-ethinyl estradiol and isotretinoin (40 mg twice daily), which she had been using for 8 months...Isotretinoin was discontinued; she was discharged with fenofibrate... Isotretinoin-induced hypertriglyceridemia leading to acute pancreatitis, though rare, should be considered when a patient on isotretinoin presents with symptoms of pancreatitis. Clinicians should be proactive in educating patients on the signs of pancreatitis and consider lipid screening, especially for those with risk factors for hypertriglyceridemia."

Clinical • Acne Vulgaris • Cardiovascular • Dermatology • Dyslipidemia • Gastroenterology • Hypertriglyceridemia • Pain • Pancreatitis

Hormonal contraceptive use and anaemia: a nation-wide pharmacoepidemiological study from Northern Europe. (PubMed, Eur J Epidemiol) - "Individual product effects ranged from 0·77 [0·66-0·90] for drospirenone and ethinylestradiol to 0·40 [0·32-0·48] for desogestrel-only. Benefits of HC use extend to anaemia protection on population level. Anaemia protection should be included in guidelines on HC to support clinical decision making."

Journal • Anemia • Genetic Disorders • Hematological Disorders • Long-acting Reversible Contraceptives • Obesity • Oncology • Women's Health

Use of systemic hormonal contraception and risk of depression: a registry-based study from Finland. (PubMed, Eur J Epidemiol) - "Use of HC in the six preceding months, specifically that of combined hormonal contraceptives (containing gestodene and ethinylestradiol, drospirenone and ethinylestradiol, and nomegestrol and estradiol), was significantly associated with a lower risk of depression compared to non-use when controlling for marital status, socioeconomic status, education, recent delivery, recent psychiatric hospitalization, chronic diseases, use of psychiatric medications (excluding antidepressants) and former use of HC (odds ratio: 0.90, 95% confidence interval = 0.85-0.95; 0.86, 95% confidence interval = 0.81-0.91, respectively). Current use of progestogen-only preparations (norethisterone, levonorgestrel, desogestrel) was not associated with depression. This pattern was evident in all age groups, including adolescent girls. HC use appeared not associated with an increased risk of depression in fertile-aged women and across all age groups, including adolescent girls."

Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

Sustained Metabolic Improvements with Low-Dose Metformin Combined with Oral Contraceptives in Female Adolescents with PCOS: A Single-Center Retrospective Cohort Study. (PubMed, Adv Ther) - "Our study highlights the effectiveness of low-dose metformin therapy in improving insulin resistance and metabolic parameters among adolescent patients with PCOS. Sustained benefits were observed even after treatment cessation. These findings underscore the potential for early intervention with metformin during adolescence to confer long-lasting advantages in managing metabolic abnormalities associated with PCOS."

Journal • Retrospective data • Polycystic Ovary Syndrome

Efficacy of a four-drug combined regimen compared to uterine curettage in the treatment of incomplete medical abortion: a prospective observational study. (PubMed, J Health Popul Nutr) - "The combined regimen of four drugs boasts favorable efficacy for the treatment of incomplete MA, and is equally efficient as compared to uterine curettage."

Journal • Observational data

Decreased Incidence of ACL Injuries in Females by Selective Use of Hormonal Contraceptives (AAOS 2025) - "Among these groups, non-contraceptive users, hormonal systemic contraceptive (including pill, implant, injection, ring, and patch) users, OCP users (including formulations norethindrone (NE) only, drospirenone (DS) + ethinyl estradiol (EE), (NE + EE), norgestimate (NG + EE)), and levonorgestrel (a progestin found in intra-uterine devices) users were included in the analysis. Hormonal contraceptive use may be associated with a lower incidence of ACL injuries compared to no contraceptive use in females. Hormonal contraceptive formulations, specifically progestin containing, may play a protective role against ACL injuries in females. Further research is warranted to explore confounding variables that impact the association between hormonal contraceptive use and ACL injury."

Long-acting Reversible Contraceptives • Orthopedics